A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients

Abstract

NEVIRAPINE, a potent and selective noncompetitive inhibitor of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), belongs to the class of antiretroviral compounds referred to as nonnucleoside reverse transcriptase inhibitors.^1,2 Nevirapine has a wide distribution throughout body tissues, including the central nervous system.^3-5 Nevirapine has at least an additive in vitro antiviral effect with zidovudine, didanosine, and lamivudine, regardless of prior zidovudine exposure.⁶